# Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

> **NCT00039585** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00039585
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039585, "Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00039585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*